Babies breaking bad: Neonatal and iatrogenic withdrawal syndromes

Current Opinion in Pediatrics

Volumn 25, Issue 4, 2013, Pages 532-542

  Cramton, Rachel E M ^a,b   Gruchala, Nancy E ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b BANNER HEALTH   (United States)

Author keywords

buprenorphine; methadone; neonatal abstinence syndrome; opiate withdrawal

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; CLONIDINE; METHADONE; MORPHINE; PHENOBARBITAL;

ADD ON THERAPY; ADJUVANT THERAPY; ARTIFICIAL VENTILATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG MEGADOSE; FEVER; GENETIC VARIABILITY; HUMAN; IATROGENIC DISEASE; LOOSE FECES; MAINTENANCE DRUG DOSE; NEWBORN DISEASE; NORADRENALIN RELEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SNEEZING; TREATMENT DURATION; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; BUPRENORPHINE; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84880789759     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328362cd0d     Document Type: Review

References (53)

1. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated healthcare expenditures: United States, 2000-2009. JAMA 2012; 307:1934-1940.
2. Kraft WK, van den Anker JN. Pharmacological management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am 2012; 59:1147-1165.
3. American Academy of Pediatrics Committee on Drugs and Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics 2012; 129:e540-e560.
4. Anand KJS, Willson DF, Berger J, et al. Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 2010; 125:e1208-e1225.
5. Jansson LM, Dipietro JA, Elko A, et al. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend 2010; 109:198-204.
6. Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199:396e1-396e7.
7. Logan BA, Brown MS, Hayes MJ. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin Obstet Gynecol 2013; 56:186-192.
8. Jansson LM, Dipietro JA, Elko A, et al. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med 2007; 20:677-685.
9. Holbrook A, Kaltenbach K. Gender and NAS: does sex matter? Drug Alcohol Depend 2010; 112:156-159.
10. Unger A, Jagsch R, Bawert A, et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? Gend Med 2011; 8:355-364.
11. Wachman E, Hayes M, Paul J, et al. Association of OPRM1 and COMT singlenucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 17:1821-1827.
12. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011; 5:293-299.
13. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012; 41:180-190.
14. Ista E, van Dijk M, Gamel C, et al. Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review. 'Assessment remains troublesome'. Intens Care Med 2007; 33:1396-1406.
15. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998; 101:1079-1088.
16. Pizarro D, Habli M, Grier M, et al. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat 2011; 40:295-298.
17. Fonsmark L, Rasmussen YH, Carl P. Occurrence of withdrawal in critically ill sedated children. Crit Care Med 1999; 27:196-199.
18. Katz R, Kelly HW, Hsi A. Prospective study on the occurrence of withdrawal in critically ill children who receive fentanyl by continuous infusion. Crit Care Med 1994; 22:763-767.
19. Ista E, Dijk M, Gamel C, et al. Withdrawal symptoms in critically ill children after long-term administration of sedatives and/or analgesics: a first evaluation. Crit Care Med 2008; 36:2427-2432.
20. Robertson RC, Darsey E, Fortenberry JD, et al. Evaluation of an opiateweaning protocol using methadone in pediatric intensive care unit patients. Pediatr Crit Care Med 2000; 1:119-123.
21. Jeffries SA, McGloin R, Pitfield AF, Carr RR. Use of methadone for prevention of opioid withdrawal in critically ill children. Can J Hosp Pharm 2012; 65:12-18.
22. Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the withdrawal assessment tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. Pain 2012; 153:142-148.
23. Ista E, van Dijk M, de Hoog M, et al. Construction of the Sophia observation withdrawal symptoms-scale (SOS) for critically ill children. Intensive Care Med 2009; 35:1075-1081.
24. Franck LS, Harris SK, Soetenga DJ, et al. The withdrawal assessment toolversion 1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med 2008; 9:573-580.
25. Gaalema DE, Linares Scott T, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphineexposed neonates. Addiction 2012; 107:53-62.
26. Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol 1975; 12:19-32.
27. Finnegan LP. Neonatal abstinence. In: Nelson NM, editor. Current Therapy in Neonatal-Perinatal Medicine. Toronto, Ontario: BC Decker Inc; 1985 . pp. 262-270.
28. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Rabaltelli FF, Grandi B, editors. Neonatal Therapy: an update. Elsevier Science Publishers B.V. (Biomedical Division); 1986. pp. 122-146.
29. Dow K, Ordean A, Murphy-Oikonen J, et al. Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol 2012; 19:e488-e506.
30. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006; 26:15-17.
31. Lucas K, Knobel RB. Implementing practice guidelines and education to improve care of infants with neonatal abstinence syndrome. Ad Neonatal Care 2012; 12:40-45.
32. Bowens CD, Thompson JA, Thompson MT, et al. A trial of methadone tapering schedules in pediatric intensive care unit patients exposed to prolonged sedative infusions. Pediatr Crit Care Med 2011; 12:504-511.
33. Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines on sedation and analgesia in critically ill children. Intens Care Med 2006; 32:1125-1136.
34. Easley RB, Nichols DG. Withdrawal assessment in the pediatric intensive care unit: quantifying a morbidity of pain and sedation management in the critically ill child. Crit Care Med 2008; 36:2479-2480.
35. Ista E, van der Voort E. Assessment of withdrawal symptoms in pediatric intensive care patients, a newfuture? Pediatr Crit CareMed 2008; 9:654-655.
36. Napolitano A, Theophilopoulos D, Seng SK, Calhoun DA. Pharmacologic management of neonatal abstinence syndrome in a community hospital. Clin Obstet Gynecol 2013; 56:193-201.
37. McQueen KA, Murphy-Oikenon J, Gerlach K, et al. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care 2011; 11:282-290.
38. Ballard JI. Treatment of neonatal abstinence syndrome with breastmilk containing methadone. J Perinat Neonatal Nurs 2002; 15:76-85.
39. Raith W, Kutschera J, Muller W, et al. Active ear acupuncture points in neonates with neonatal abstinence syndrome (NAS). Am J Chin Med 2011; 39:29-37.
40. Osborne DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2009; CDOO2053.
41. Osborne DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2009; CDOO2059.
42. Jannson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24:252-258.
43. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008; 122:e601-e607.
44. Broom L, So T. Neonatal abstinence syndrome: the use of clonidine as a treatment option. Neoreviews 2011; 12:e574-e583.
45. Isemann B, Meinzen-Derr J, Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol 2011; 31:25-29.
46. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized controlled trial. Pediatrics 2009; 123:e849-e856.
47. McLemore GL, Lewis T, Jones CH, Gauda EB. Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. Semin Fetal Neonatal Med 2013; 35-41.
48. Darnell CM, Thompson J, Stromberg D, et al. Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children. Pediatrics 2008; 121:e1363-e1371.
49. Honey BL, Benefield RJ, Miller JL, Johnson PN. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 2009; 43:1506-1511.
50. Oschman A, McCabe T, Kuhn RJ. Dexmedetomidine for opioid and benzodiazepine withdrawal in pediatric patients. Am J Health Syst Pharm 2011; 68:1233-1238.
51. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007; 87:131-138.
52. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320-2331.
53. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96:69-78.